Few areas of men's health have shifted as much in the last two decades as prostate cancer screening. The pendulum swung from routine annual PSA tests for every man over fifty to strong warnings about overdiagnosis, and has now settled into a middle position that emphasizes shared decision-making. That middle position is more nuanced, and more useful, than either extreme.
This piece walks through the current state of screening and the tradeoffs that make the decision genuinely individual.
Two different problems, one name
Prostate issues in men generally fall into three categories that get confused with each other:
- Benign prostatic hyperplasia (BPH), the enlargement that causes weak stream, frequency, and nighttime urination
- Prostatitis, inflammation or infection that can be acute or chronic
- Prostate cancer, which is often slow-growing but can be aggressive
BPH and prostate cancer are not causally linked, and treatment for one does not prevent the other. Symptoms that feel urgent, waking multiple times at night, difficulty starting a stream, incomplete emptying, are more often BPH than cancer, but they deserve evaluation.
What the screening debate is really about
PSA, prostate-specific antigen, is a blood test that measures a protein produced by prostate cells. It rises with cancer, but also with BPH, prostatitis, recent ejaculation, cycling, and simple age. That non-specificity is the source of the entire controversy.
The USPSTF currently recommends that men aged 55 to 69 make an individual decision about PSA screening after discussing the potential benefits and harms with their clinician, and recommends against routine screening for men 70 and older. The AUA suggests offering baseline PSA discussion starting at 45 for average-risk men, and at 40 for men at higher risk, which includes Black men and men with a first-degree relative diagnosed with prostate cancer.
The benefit of screening is a modest reduction in prostate cancer mortality. The harms are more concrete than they sound:
- False positives leading to biopsies, which carry risks of infection and bleeding
- Overdiagnosis of cancers that would never have caused symptoms in a man's lifetime
- Overtreatment through surgery or radiation, which can cause lasting incontinence and erectile dysfunction
How screening has changed
The modern approach reduces the harms by adding steps between an elevated PSA and a biopsy. If your PSA is elevated, reasonable next steps often include:
- Repeating the test after several weeks, since transient elevations are common
- PSA density, which adjusts the value for prostate size
- Free-to-total PSA ratio or blood-based tests like the 4Kscore or PHI
- Multiparametric MRI before biopsy, which can identify suspicious lesions and spare men without them from unnecessary procedures
When biopsy is warranted, transperineal approaches have lower infection risk than the older transrectal method. And when cancer is found, active surveillance, monitoring rather than treating low-risk disease, has become the standard for most Gleason 6 (Grade Group 1) tumors.
Active surveillance is not doing nothing. It is a structured program of PSA testing, imaging, and repeat biopsy designed to catch the small fraction of low-risk cancers that turn aggressive, without exposing the majority of men to treatment they would never have needed.
Talking to your clinician
The useful conversation is not whether to test but what the result would change. Questions worth asking:
- Given my age, family history, and race, what is my baseline risk?
- If my PSA is elevated, what is your next step, MRI or straight to biopsy?
- If I am diagnosed with low-risk cancer, would you offer active surveillance?
- At what age would you stop screening me?
A clinician who moves straight from a mildly elevated PSA to biopsy without MRI or repeat testing is practicing an older standard.
The bottom line
Prostate cancer screening is a real decision, not a reflex. For men in their fifties and sixties, an informed conversation about PSA, ideally with a clinician who uses MRI and supports active surveillance for low-risk disease, is the current standard. Screening has become smarter, and the men who benefit most are the ones who understand what they are opting into.